Published
Samuel Cytryn, MD, Memorial Sloan Kettering Cancer Center, highlights how new data—including the recent New England Journal of Medicine study on neoadjuvant dostarlimab—underscore the exceptional sensitivity of MSI-high gastric cancers to immune checkpoint blockade, prompting a potential shift in treatment paradigms.
- Categoria
- Oncology
Commenta per primo questo video.
Prossimo
-
14:05
How Immunotherapy Controls Cancer | New Cancer Treatment | Immunotherapy Future of Cancer Treatment
-
15:56
Understanding ctDNA: A New Tool for Bladder Cancer Care. Part 2 of 4
-
05:13
Understanding ctDNA in Breast Cancer
-
04:42
At 78, She Beats Recurrence of Pancreatic Cancer After MRI-Guided Radiation Therapy
-
07:55
Immunotherapy सब Cancer Patient को क्यों नहीं दी जाती? | Immunotherapy In Cancer! |Dr Praveen Kammar
-
05:17
When Is Immunotherapy Given? Understanding Cancer Immunotherapy | Dr. Anup Toshniwal
-
09:08
Cancer कैसे फैलता है, Cancer Stages, Survival Rate, Treatment & Cancer Recurrence I Dr Kaushal Yadav
-
07:26
Guided by Liquid Biopsy: Bob’s Journey Through Stage 4 Gastric Cancer
-
12:17
Dr. Ben Park on ctDNA: Precision Oncology in Breast Cancer at SABCS 2024
-
04:15
Implications of low ctDNA detectability in peritoneal metastases from colon cancer
-
09:07
Cardiology for Beginners: Basics of Heart Sounds and Murmurs (with examples)
-
13:45
How to Become a Cardiologist | Cardiac Electrophysiologist
-
04:14
V 00592 Cardiology Fellowship Video Dr Vranian V5
-
05:17
Cardiology Fellowship at SIU Medicine
-
04:15
Cardiology Fellowship Program at Danbury Hospital
-
05:49
Practice Question: Cardiology #1, USMLE Step 1, COMLEX Level 1
-
04:07
Dr. Muhammed Raza on advice for Fellows interested in Interventional Cardiology
-
07:36
Congenital Heart Disease – Cardiology | Lecturio
-
05:18
Cardiology Fellowship at IU School of Medicine
-
04:36
What are different types of Cardiology Tests | SPS Hospitals
